Currently, the feasibility, safety, and preliminary efficacy of anti-CD133 CAR-T cells targeting CD133 in advanced malignant tumors (e.g., hepatocellular carcinoma) have been shown in phase I clinical trials (157). This evidence concerns the gene PROM1 and cancer.